Articles Analyze Debate Surrounding Female Sexual Dysfunction Drug Flibanserin

The Los Angeles Times and New York Times recently examined issues related to the experimental female libido drug flibanserin. On June 18, an FDA advisory panel voted 11-0 against recommending the drug for treatment of female hypoactive sexual-desire disorder. Summaries appear below…

Related posts:

  1. Advisory Panel Says FDA Should Not Approve Drug To Address Female Sexual Dysfunction
  2. Washington Post Opinion Article Responds To Critics Of Female Sexual Dysfunction Drug

0 Comments. Posted by Luv2Play on Wednesday, June 30, 2010 at 6:41 pm.

Filed under STD's.

No Comments on “Articles Analyze Debate Surrounding Female Sexual Dysfunction Drug Flibanserin”

You can track this conversation through its atom feed.

No one has commented on this entry yet.

Leave a Reply

XHTML: You can use these tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>